CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

City Therapeutics will develop an RNAi clinical candidate for intravitreal administration targeting retinal diseases, including geographic atrophy. Bausch + Lomb will manage IND-enabling studies, ...

And in December, it shelved a sickle cell treatment similar to Casgevy, the treatment approved in late 2023 from Vertex and CRISPR Therapeutics. Casgevy’s slow rollout — it appears to have ...

Developed collaboratively by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy is designed to treat sickle cell disease and transfusion-dependent beta-thalassemia. The therapy involves editing ...

The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $38.36, reflecting a -1.26% shift from the previouse trading day's closing. The stock trailed the S&P 500 ...

PARIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company ... in six to twelve dry age-related macular degeneration (AMD)/geographic atrophy (GA) patients.